Outro plans to expand its tapering model into additional medication classes beyond antidepressants, including benzodiazepines, gabapentinoids, and GLP-1s.

From the articleOutro Raises $7M To Support Safe Deprescribing - MedCity NewsAlso in Outro Announces $7M in Funding to Expand Access to Safe Deprescribing, Starting With Antidepressants